Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data.
In a pilot study, the feasibility of immune whey protein concentrate (40%; immune WPC-40) to aid the prevention of relapse of Clostridium difficile diarrhoea was evaluated. Immune WPC-40 was made from milk after immunization of Holstein-Frisian cows with C. difficile-inactivated toxins and killed whole-cell C. difficile. Immune WPC-40 contained a high concentration of specific sIgA antibodies, and was effective in neutralizing the cytotoxic effect of C. difficile toxins in cell assays in vitro. Immune WPC-40 conferred protection from otherwise lethal C. difficile-associated caecitis in hamsters. To obtain preliminary data in humans, 16 patients (10 male; median 57 years) with toxin- and culture-confirmed C. difficile diarrhoea were enrolled in an uncontrolled cohort study. Nine had a history of relapsing C. difficile diarrhoea. After completion of standard antibiotic treatment, the patients received immune WPC-40 TID for 2 weeks; it was well tolerated and no treatment-related adverse effects were observed. In all but one case, C. difficile toxins had disappeared from the faeces upon completion of treatment. During a follow-up period of median 333 days (range 35 days to 1 year), none of the patients had suffered another episode of C. difficile diarrhoea. These preliminary data suggest that immune whey protein concentrate-40 may be of help in the prevention of relapse of C. difficile diarrhoea.
van Dissel
Jaap T
JT
Department of Infectious Diseases1 and Department of Medical Microbiology3, Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands 2MucoVax bv, Niels Bohrweg 11-13, Leiden, The Netherlands 4Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, USA 5Department of Internal Medicine, Bronovo Hospital, Bronovolaan 5, The Hague, The Netherlands.
de Groot
Nanda
N
Department of Infectious Diseases1 and Department of Medical Microbiology3, Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands 2MucoVax bv, Niels Bohrweg 11-13, Leiden, The Netherlands 4Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, USA 5Department of Internal Medicine, Bronovo Hospital, Bronovolaan 5, The Hague, The Netherlands.
Hensgens
Charles Mh
CM
Department of Infectious Diseases1 and Department of Medical Microbiology3, Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands 2MucoVax bv, Niels Bohrweg 11-13, Leiden, The Netherlands 4Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, USA 5Department of Internal Medicine, Bronovo Hospital, Bronovolaan 5, The Hague, The Netherlands.
Numan
Sandra
S
Department of Infectious Diseases1 and Department of Medical Microbiology3, Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands 2MucoVax bv, Niels Bohrweg 11-13, Leiden, The Netherlands 4Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, USA 5Department of Internal Medicine, Bronovo Hospital, Bronovolaan 5, The Hague, The Netherlands.
Kuijper
Ed J
EJ
Department of Infectious Diseases1 and Department of Medical Microbiology3, Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands 2MucoVax bv, Niels Bohrweg 11-13, Leiden, The Netherlands 4Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, USA 5Department of Internal Medicine, Bronovo Hospital, Bronovolaan 5, The Hague, The Netherlands.
Veldkamp
Peter
P
Department of Infectious Diseases1 and Department of Medical Microbiology3, Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands 2MucoVax bv, Niels Bohrweg 11-13, Leiden, The Netherlands 4Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, USA 5Department of Internal Medicine, Bronovo Hospital, Bronovolaan 5, The Hague, The Netherlands.
van 't Wout
Jan
J
Department of Infectious Diseases1 and Department of Medical Microbiology3, Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands 2MucoVax bv, Niels Bohrweg 11-13, Leiden, The Netherlands 4Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, USA 5Department of Internal Medicine, Bronovo Hospital, Bronovolaan 5, The Hague, The Netherlands.
D000818:Animals; D000907:Antibodies, Bacterial / Q000627:therapeutic use*; D002417:Cattle; D016360:Clostridioides difficile / Q000276:immunology*; D003015:Clostridium Infections / Q000517:prevention & control*; D015331:Cohort Studies; D006224:Cricetinae; D003967:Diarrhea / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D010865:Pilot Projects; D011446:Prospective Studies
D000907:Antibodies, Bacterial